Cambridge Investment Research Advisors
GENE

Cambridge Investment Research Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-850
Closed -$10K – 2425
2019
Q2 		$10K Hold
850
– – ﹤0.01% 2190
2019
Q1 		$15K Hold
850
– – ﹤0.01% 2261
2018
Q4 		$9K Hold
850
– – ﹤0.01% 2140
2018
Q3 		$19K Hold
850
– – ﹤0.01% 2225
2018
Q2 		$17K Buy
850
+250
+42% +$5.92K ﹤0.01% 2192
2018
Q1 		$12K Buy
+600
New +$17.3K ﹤0.01% 2134

Other funds holding GENE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Cambridge Investment Research Advisors's GENE Position: Q3 2019 in Review

Cambridge Investment Research Advisors sold out of Genetic Technologies Ltd. (GENE) in Q3 2019, closing a stake of 850 shares — an estimated $10K sold.

Cambridge Investment Research Advisors first reported a position in GENE in Q1 2018 and held it in 6 quarters. The position peaked at $19K in Q3 2018. 6 funds tracked by Wall St. Rank hold GENE as of Q3 2019.

  • Cambridge Investment Research Advisors reported no remaining Genetic Technologies Ltd. position as of Q3 2019 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 850 Genetic Technologies Ltd. shares in Q3 2019, an estimated $10K.
  • Cambridge Investment Research Advisors first reported a position in Genetic Technologies Ltd. in Q1 2018 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Genetic Technologies Ltd. position peaked at $19K in Q3 2018.
  • 6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2019, filed 28 Oct 2019.